

Human PD-1 PE-conjugated Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: FAB7115P

100 TESTS


DESCRIPTION			
Species Reactivity	y Human		
Specificity	Detects human PD-1 in ELISAs and Western blots. In sandwich ELISAs, less than 2% cross-reactivity with recombinant mouse PD-1 and than 0.2% cross-reactivity with recombinant human (rh) CD28, rhICOS, and rhCTLA-4 is observed.		
Source	Polyclonal Goat IgG		
Purification	Antigen Affinity-purified		
Immunogen	Mouse myeloma cell line NS0-derived recombinant human PD-1 Leu25-Gln167 Accession # Q8IX89		
Conjugate	Phycoerythrin Excitation Wavelength: 488 nm Emission Wavelength: 565-605 nm		
Formulation	Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.		
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.		

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Flow Cytometry	10 μL/10 ⁶ cells	See Below

DATA



Detection of PD-1 in Human PBMCs treated with PHA by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) either (A) untreated or (B) treated with 5 μg/mL PHA overnight were stained with Goat Anti-Human PD-1 PE-conjugated Antigen Affinity-purified Polyclonal Antibody (Catalog # FAB7115P) and Mouse Anti-Human CD3ε APC-conjugated Monoclonal Antibody (Catalog # FAB10A). Quadrant markers were set based on control antibody staining (Catalog # IC108P). View our protocol for Staining Membrane-associated Proteins.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Protect from light. Do not freeze.

• 12 months from date of receipt, 2 to 8 °C as supplied.

Rev. 1/25/2016 Page 1 of 2





Human PD-1 PE-conjugated Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: FAB7115P

100 TESTS

BACKGROUND

Programmed Death-1 (PD-1) is a type I transmembrane protein belonging to the CD28/CTLA-4 family of immunoreceptors that mediate signals for regulating immune responses (1). Members of the CD28/CTLA-4 family have been shown to either promote T cell activation (CD28 and ICOS) or down-regulate T cell activation (CTLA-4 and PD-1) (2). PD-1 is expressed on activated T cells, B cells, myeloid cells, and on a subset of thymocytes. *In vitro*, ligation of PD-1 inhibits TCR-mediated T-cell proliferation and production of IL-1, IL-4, IL-10, and IFN-y. In addition, PD-1 ligation also inhibits BCR mediated signaling. PD-1 deficient mice have a defect in peripheral tolerance and spontaneously develop autoimmune diseases (2, 3). Two B7 family proteins, PD-L1 (also called B7-H1) and PD-L2 (also known as B7-DC), have been identified as PD-1 ligands. Unlike other B7 family proteins, both PD-L1 and PD-L2 are expressed in a wide variety of normal tissues including heart, placenta, and activated spleens (4). The wide expression of PD-L1 and PD-L2 and the inhibitor effects on PD-1 ligation indicate that PD-1 might be involved in the regulation of peripheral tolerance and may help prevent autoimmune diseases (2). The human PD-1 gene encodes a 288 amino acid (aa) protein with a putative 20 as signal peptide, a 148 aa extracellular region with one immunoglobulin-like V-type domain, a 24 aa transmembrane domain, and a 95 aa cytoplasmic region. The cytoplasmic tail contains two tyrosine residues that form the immuno-receptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important in mediating PD-1 signaling. Mouse and human PD-1 share approximately 60% aa sequence identity (4).

References:

- 1. Ishida, Y. et al. (1992) EMBO J. 11:3887.
- Nishimura, H. and T. Honjo (2001) Trends in Immunol. 22:265.
- 3. Latchman, Y. et al. (2001) Nature Immun. 2:261.
- 4. Carreno, B.M. and M. Collins (2002) Annu. Rev. Immunol. 20:29.